Works matching AU Sun, Liangdong


Results: 23
    1
    2
    3
    4
    5
    6
    7

    Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.

    Published in:
    BMC Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12916-022-02696-4
    By:
    • Zhu, Xinsheng;
    • Sun, Liangdong;
    • Song, Nan;
    • He, Wenxin;
    • Xie, Boxiong;
    • Hu, Junjie;
    • Zhang, Jing;
    • Yang, Jie;
    • Dai, Jie;
    • Bian, Dongliang;
    • Xia, Haoran;
    • Sun, Fenghuan;
    • Xiong, Anwen;
    • Luo, Jie;
    • Zhang, Lele;
    • Yu, Huansha;
    • Liu, Ming;
    • Liu, Hongcheng;
    • Wang, Haifeng;
    • Zhang, Haiping
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15

    3D Printing of Bioinspired Liquid Superrepellent Structures.

    Published in:
    Advanced Materials, 2018, v. 30, n. 22, p. 1, doi. 10.1002/adma.201800103
    By:
    • Liu, Xiaojiang;
    • Gu, Hongcheng;
    • Wang, Min;
    • Du, Xin;
    • Gao, Bingbing;
    • Elbaz, Abdelrahman;
    • Sun, Liangdong;
    • Liao, Julong;
    • Xiao, Pengfeng;
    • Gu, Zhongze
    Publication type:
    Article
    16
    17
    18
    19
    20

    Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.

    Published in:
    Signal Transduction & Targeted Therapy, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41392-024-01861-w
    By:
    • Xia, Haoran;
    • Zhang, Han;
    • Ruan, Zheng;
    • Zhang, Huibiao;
    • Sun, Liangdong;
    • Chen, Hezhong;
    • Zhou, Yongxin;
    • Zhang, Lele;
    • Bian, Dongliang;
    • Zhu, Xinsheng;
    • Zhang, Jing;
    • Sun, Fenghuan;
    • Yu, Huansha;
    • Song, Nan;
    • Liu, Xiaogang;
    • Zhu, Yuming;
    • Zhang, Haiping;
    • He, Wenxin;
    • Chen, Jian;
    • Yang, Jie
    Publication type:
    Article
    21
    22
    23